Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabenazine SCHEMBL12394431 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29383441 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL13401094 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29609598 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971241 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992567 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL16992566 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL9971276 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL20049732 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB | |
| Tetrabenazine SCHEMBL29380971 | 1.00 | SLC18A2 (1.00) | SLC18A2KDM4EABCB11ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10755 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12616680-B2 | Combined use of biotin and thiamine in the treatment of huntington's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2026-05-05 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108201-A1 | MOVEMENT DISORDER DETECTION AND ASSESSMENT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2026-04-23 | — | — | US | claimed |
| US-12599598-B2 | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof | AUSPEX PHARMACEUTICALS LLC (US) | 2026-04-14 | — | — | US | claimed |
| US-20260083700-A1 | METHODS FOR TREATING AND/OR PREVENTING PROTEIN-AGGREGATION DISEASES | UNIV PABLO DE OLAVIDE (ES) | 2026-03-26 | — | — | US | claimed |
| US-12583860-B2 | Processes for the preparation of multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour | APOTEX INC. (CA) | 2026-03-24 | — | — | US | claimed |
| US-12578348-B2 | Blood indicators of Alzheimer's disease | THE INSTITUTE FOR ETHNOMEDICINE (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-1439858-A1 | USE OF GRANULAR MATERIALS BASED ON PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS | Degussa AG (DE) | 2004-07-28 | — | — | EP | claimed |
| US-20040022844-A1 | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions | EVONIK OPERATIONS GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| WO-2003037379-A1 | USE OF GRANULAR MATERIALS BASED ON PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS | DEGUSSA AG (DE) | 2003-05-08 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1998042723-A9 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | — | 1999-03-04 | — | — | WO | claimed |
| CN-1113270-A | Preparation for organic inclusion compound large crystal with second-order nonlinear optical effect | UNIV LIAONING NORMAL (CN) | 1995-12-13 | — | — | CN | claimed |
| WO-1993025699-A1 | VESICLE MEMBRANE TRANSPORT PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-12-23 | — | — | WO | claimed |
| US-4316897-A | TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |